BioSpace News Archive

Immunome, Inc. today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time.

Astria Therapeutics, Inc. today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas on May 16, 2024.

STRATA Skin Sciences, Inc. announces that it will report first quarter 2024 financial results on Wednesday, May 15, 2024 after the market close.

Indaptus Therapeutics, Inc. today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Belite Bio, Inc today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2024.

Rakovina Therapeutics Inc. is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform.

Spero Therapeutics, Inc. today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close.

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO™ 3 System Version 8, the latest version of the company’s leading three-dimension heart mapping system used in cardiac ablation procedures.

Solarea Bio, a Boston-based clinical-stage biotechnology company, recognizes this and believes that it is essential to not only raise awareness around the importance of bone health far ahead of menopause, but to also provide consumers with tangible avenues for managing bone loss leading up to and throughout the menopausal experience.

Lipocine Inc., a biopharmaceutical company, announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver Congress, to take place June 5 to 8, 2024 in Milan, Italy.